Naphcon A

Naphcon-A relieves itching and redness due to allergies. can cause blurred vision. do not drive until you know how this medication affects you.

Naphcon A Overview


Naphcon-A is an over the counter medication used to treat eye itching and redness due to allergies in adults and children over 6 years of age.

Naphcon A contains 2 ingredients: naphazoline and pheniramine. Naphazoline belongs to a group of drugs called redness relievers. Pheniramine belongs to a group of drugs called antihistamines. Together these work by constricting the blood vessels in the eye and blocking the substances that cause allergies.

This medication comes in eye drop solution and is used up to four times a day.

Common side effects of Naphcon-A include stinging, redness, and blurred vision.


How was your experience with Naphcon A?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Naphcon A?

What are you taking Naphcon A for?

Choose one
  • Other
  • Hyperemia
  • Rhinitis
  • Rhinitis, Allergic, Perennial
  • Sinusitis
  • Urticaria

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Naphcon A work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Naphcon A to a friend?



Naphcon A consists of multiple generic medications. The generic medications are listed below.


For more information on this medication choose from the list of selections below.


For more information on this medication choose from the list of selections below.

Naphcon A Drug Class

Naphcon A is part of the drug class:


All RxWiki content including health news, medication pages, and condition pages published prior to February 2023, was written and maintained by on-staff pharmacists. Please be advised that this content is no longer actively maintained and may now contain outdated information. If you have any questions regarding previously published content, please contact